{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:22Z","timestamp":1787020642210,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eosinophilic fasciitis (EF) is a rare disease characterized by skin induration and musculoskeletal abnormalities. Diagnostic criteria for EF are based on adult populations. There is a need to expand the literature on EF in children due to limited reported cases and potential differences compared to adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of medical records for six pediatric patients diagnosed with EF at our institution between November 2011 and April 2023. Inclusion criteria required patients to be under 18\u00a0years of age at the time of diagnosis and to have confirmed diagnosis through clinical history, imaging, and histology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most of our cohort were female (83%) and non-Hispanic white (50%). Age at diagnosis ranged from 4 to 16\u00a0years. Duration of symptoms before diagnosis varied from 1 to 12\u00a0months. Follow-up periods ranged from 14 to 123\u00a0months. Concurrent medical conditions included localized scleroderma, acquired thrombophilia, and juvenile idiopathic arthritis. Patients presented with progressive painful swelling, severe joint limitations, and positive prayer sign. Initial regimens involved corticosteroids and methotrexate. Hydroxychloroquine, immunoglobulin, mycophenolate mofetil, rituximab, and tocilizumab were also used depending on the patient\u2019s disease severity and course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Juvenile EF may manifest as swelling and progressive induration without apparent skin abnormalities. Unlike adult populations, no underlying malignancies or associations with trauma were observed in our cohort. Our cases did not exhibit systemic involvement observed in previous studies on juvenile EF. While non-specific, the prayer sign may aid in early recognition of juvenile EF and help prevent long-term disability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-024-00960-w","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:18:31Z","timestamp":1708719511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Juvenile eosinophilic fasciitis: a single center case series"],"prefix":"10.1186","volume":"22","author":[{"given":"Leigh A.","family":"Stubbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun","family":"Ogunbona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Beil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Szafron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle","family":"Adesina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Anvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Ditzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-6293","authenticated-orcid":false,"given":"Marietta","family":"DeGuzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"issue":"4","key":"960_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.clindermatol.2018.04.006","volume":"36","author":"N Fett","year":"2018","unstructured":"Fett N, Arthur M. Eosinophilic fasciitis: Current concepts. Clin Dermatol. 2018;36(4):487\u201397.","journal-title":"Clin Dermatol"},{"key":"960_CR2","volume-title":"Textbook of Pediatric Rheumatology","author":"SC Li","year":"2021","unstructured":"Li SC, Pope E. Textbook of Pediatric Rheumatology. In: Petty RE, Wedderburn LR, Laxer RM, Mellins ED, Lindsley CB, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8th ed. Philadelpha, Pennsylvania: Elseiver; 2021.","edition":"8"},{"issue":"8","key":"960_CR3","first-page":"1811","volume":"30","author":"C Toquet","year":"2003","unstructured":"Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, et al. In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol. 2003;30(8):1811\u20135.","journal-title":"J Rheumatol"},{"issue":"2","key":"960_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2133.2004.06062.x","volume":"151","author":"M Jinnin","year":"2004","unstructured":"Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K. Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. Br J Dermatol. 2004;151(2):407\u201312.","journal-title":"Br J Dermatol"},{"issue":"3","key":"960_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","volume":"53","author":"C Ferreli","year":"2017","unstructured":"Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol. 2017;53(3):306\u201336.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"960_CR6","first-page":"614","volume":"45","author":"F Zulian","year":"2005","unstructured":"Zulian F, Athreya BH, Laxer R, Nelson AM, et al. Feitosa de Oliveira SK, Punaro MG, Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study Rheumatology. 2005;45(5):614\u201320.","journal-title":"An international study. Rheumatology."},{"issue":"1","key":"960_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamadermatol.2015.3648","volume":"152","author":"NA Wright","year":"2016","unstructured":"Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA. Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers. JAMA Dermatol. 2016;152(1):97\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4\u20135","key":"960_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","volume":"13","author":"I Pinal-Fernandez","year":"2014","unstructured":"Pinal-Fernandez I, Selva-O\u2019 Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev. 2014;13(4\u20135):379\u201382.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"960_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1346-8138.14160","volume":"45","author":"M Jinnin","year":"2018","unstructured":"Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol. 2018;45(8):881\u201390.","journal-title":"J Dermatol"},{"issue":"12","key":"960_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-017-0700-6","volume":"19","author":"DR Mazori","year":"2017","unstructured":"Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep. 2017;19(12):74.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"960_CR11","first-page":"569","volume":"11","author":"LE Shulman","year":"1984","unstructured":"Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol. 1984;11(5):569\u201370.","journal-title":"J Rheumatol"},{"issue":"3","key":"960_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/RHU.0b013e3181d56f73","volume":"16","author":"K Loupasakis","year":"2010","unstructured":"Loupasakis K, Derk CT. Eosinophilic fasciitis in a pediatric patient. J Clin Rheumatol. 2010;16(3):129\u201331.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"960_CR13","first-page":"527","volume":"34","author":"R Papa","year":"2016","unstructured":"Papa R, Nozza P, Granata C, Caorsi R, Gattorno M, Martini A, Picco P. Juvenile eosinophilic fasciitis: three case reports with review of the literature. Clin Exp Rheumatol. 2016;34(3):527\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"960_CR14","first-page":"e220237","volume":"1","author":"TM Coimbra","year":"2022","unstructured":"Coimbra TM, Santos JBd, Shinkado YR, Delicato G, Arimura AM, Paiva EFd, Lichtenstein A. Eosinophilic Fasciitis: Clinical Signs Leading to Diagnosis. Annals of Internal Medicine: Clinical Cases. 2022;1(8):e220237.","journal-title":"Annals of Internal Medicine: Clinical Cases"},{"issue":"6","key":"960_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/pde.14327","volume":"37","author":"TT Wu","year":"2020","unstructured":"Wu TT, Goodarzi H, Wang J, Novoa R, Teng JMC. Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis. Pediatr Dermatol. 2020;37(6):1171\u20132.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"960_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1756-185X.12499","volume":"18","author":"F Berianu","year":"2015","unstructured":"Berianu F, Cohen MD, Abril A, Ginsburg WW. Eosinophilic fasciitis: clinical characteristics and response to methotrexate. Int J Rheum Dis. 2015;18(1):91\u20138.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"960_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","volume":"51","author":"D Lebeaux","year":"2011","unstructured":"Lebeaux D, Franc\u00e8s C, Barete S, Wechsler B, Dubourg O, Renoux J, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology. 2011;51(3):557\u201361.","journal-title":"Rheumatology"},{"issue":"4","key":"960_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.rdc.2021.07.014","volume":"47","author":"N Vasquez-Canizares","year":"2021","unstructured":"Vasquez-Canizares N, Li SC. Juvenile Localized Scleroderma: Updates and Differences from Adult-Onset Disease. Rheum Dis Clin North Am. 2021;47(4):737\u201355.","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"960_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamadermatol.2016.2873","volume":"152","author":"JS Mertens","year":"2016","unstructured":"Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, et al. High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. JAMA Dermatol. 2016;152(11):1262\u20135.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"960_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.1780240508","volume":"24","author":"LT Kent","year":"1981","unstructured":"Kent LT, Cramer SF, Moskowitz RW. Eosinophilic fasciitis: clinical, laboratory, and microscopic considerations. Arthritis Rheum. 1981;24(5):677\u201383.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"960_CR21","first-page":"65","volume":"24","author":"M Scheinberg","year":"2006","unstructured":"Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002\u20132004). Clin Exp Rheumatol. 2006;24(1):65\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"960_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/rheumatology\/keq062","volume":"49","author":"D Khanna","year":"2010","unstructured":"Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford). 2010;49(6):1184\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"960_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/rheumatology\/ken142","volume":"47","author":"N Tzaribachev","year":"2008","unstructured":"Tzaribachev N, Holzer U, Schedel J, Maier V, Klein R, Kuemmerle-Deschner J. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford). 2008;47(6):930\u20132.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"960_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s10067-020-04952-5","volume":"39","author":"F V\u00edlchez-Oya","year":"2020","unstructured":"V\u00edlchez-Oya F, S\u00e1nchez-Schmidt JM, Agust\u00ed A, Pros A. The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review. Clin Rheumatol. 2020;39(5):1693\u20138.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"960_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"960_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 2010;62(2):219\u201325.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"960_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.21687","volume":"64","author":"SC Li","year":"2012","unstructured":"Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012;64(8):1175\u201385.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-024-00960-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-024-00960-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:18:59Z","timestamp":1708719539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-024-00960-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["960"],"URL":"https:\/\/doi.org\/10.1186\/s12969-024-00960-w","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Baylor College of Medicine IRB (#H-37047).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented to the publication of the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}